The State Pharmaceuticals Corporation (SPC) of Sri Lanka reported a significant increase in its contributions to the government in 2025, with income tax and treasury levies rising by 173 percent compared with 2024, reaching Rs. 1.118 billion.
According to the SPC’s annual progress report, this marks one of the strongest financial years in the corporation’s recent history. The increase reflects higher revenue generation across SPC’s operations and demonstrates its growing role as a key partner in supporting government finances.
SPC, which has been supplying quality-assured medicines to Sri Lanka’s healthcare system for over 53 years, remains committed to maintaining affordable access to essential medicines while contributing to national development.
